European Medicines Agency CHMP Recommends EU Approval of Partner Therapeutics IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Haematopoietic Sub-syndrome of Acute Radiation Syndrome) ...Middle East

LEXINGTON, Mass., June 20, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of PTx's Marketing Authorisation Application (MAA) for IMREPLYS®...

Read More Details
Finally We wish PressBee provided you with enough information of ( European Medicines Agency CHMP Recommends EU Approval of Partner Therapeutics IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Haematopoietic Sub-syndrome of Acute Radiation Syndrome) )

Also on site :

• Country 'MVP' Refunds Entire Audience Mid-Concert and Fans 'Cannot Believe He Did That'
• With Property Seized and Federal Funding Uncertain, Montana Asbestos Clinic Fights for Its Life
• Trump fija nuevo plazo de negociación de dos semanas y desencadena esfuerzo urgente por reanudar las conversaciones con Irán